By Fineline Cube 
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC, a urothelial carcinoma assay for early detection of urinary system tumors. The milestone event took place at the Huadong Hospital Affiliated to Fudan University in Shanghai.
AcornMed’s Product Portfolio
AcornMed, established in 2018, has developed a range of innovative products for urological cancer detection and follow-up. These include utLIFE-UC for early detection of urothelial carcinoma, AcornUI-MRD for follow-up examinations, and AcornUPro-SEEK for prostate cancer early detection. All three products have been recognized with Breakthrough Device Designations by the US Food and Drug Administration (FDA).
Grand Pharma’s Collaboration
Grand Pharma holds exclusive commercialization and co-development rights for these products in mainland China. This strategic partnership underscores the company’s commitment to advancing early detection and follow-up care for urological cancers.
Clinical Performance of utLIFE-UC
Clinical study data from over 1000 regulatory studies demonstrate the high efficacy of utLIFE-UC. The assay achieves a sensitivity of 92.5% and a specificity of 95.8%. Notably, its results are not influenced by external factors such as hematuria and stones, making it a reliable tool for early detection of urothelial carcinoma.-Fineline Info & Tech